---
title: United Therapeutics CEO Martine Rothblatt Sold About $2.2M in March 2026 as UTHR Sat Near Record Results
type: news
slug: united-therapeutics-martine-rothblatt-sold-2-2m-after-record-revenue-2026-03
canonical_url: https://13finsight.com/news/united-therapeutics-martine-rothblatt-sold-2-2m-after-record-revenue-2026-03
published_at: 2026-04-17T10:26:25.853Z
updated_at: 2026-04-17T10:26:28.169Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 375
locale: en
source: 13F Insight
---

# United Therapeutics CEO Martine Rothblatt Sold About $2.2M in March 2026 as UTHR Sat Near Record Results

> United Therapeutics CEO Martine Rothblatt sold roughly $2.2 million of UTHR stock across visible March 2026 Form 4 sale lines. The trades landed after the company reported record 2025 revenue and while UTHR still traded at $580.51 on April 17, 2026.

United Therapeutics CEO Martine Rothblatt sold stock in a series of visible March 2026 Form 4 lines totaling roughly $2.2 million. Those sales came after UTHR reported record full-year 2025 revenue and while the stock was still trading at $580.51 on April 17, 2026. That combination makes the filing notable, but not automatically bearish.TL;DRSeller: Martine Rothblatt, Chairperson and CEO of United Therapeutics.Approx. sale value: about $2.2M across the visible March 2026 sale lines.Business backdrop: United Therapeutics reported record 2025 revenue of $3.18B.Why investors care: Rothblatt is closely tied to the company’s strategic identity and long-term growth narrative.Stock context: UTHR was at $580.51 on April 17, 2026.Transaction SnapshotWindowInsiderActionApprox. valueWhy readers careMarch 12-16, 2026Martine RothblattExercise-related sales~$2.2MThe transactions landed right after a record revenue year and ahead of additional long-term catalysts.Why The Market Cares NowUnited Therapeutics reported full-year 2025 revenue of about $3.18 billion, up 11% from 2024, and fourth-quarter revenue of $790.2 million. The company highlighted another year of record total revenue, strong Tyvaso growth, and management commentary about potential transformational clinical readouts. It also disclosed share repurchase activity through accelerated repurchase agreements totaling roughly $2.0 billion in aggregate across the two programs discussed in the release. In other words, Rothblatt sold into a business story that still looked fundamentally strong.What The Filing Probably MeansThe visible pattern reads more like exercise-related monetization than a sudden vote against the company. The latest sales were relatively small compared with Rothblatt’s historical relevance to United Therapeutics, and the broader ownership picture still included beneficial ownership signals in company-related 13G filings. Investors should be careful not to flatten a nuanced founder-CEO ownership story into a one-line “sold stock” headline.What To Watch NextThe follow-up question is whether the selling remains isolated and mechanical while United Therapeutics keeps delivering on Tyvaso growth and future clinical milestones. If the company’s operating story remains intact, this filing is more likely to be viewed as routine executive liquidity inside a still-constructive fundamental backdrop.Q&AHow much UTHR did Martine Rothblatt sell?Based on the visible March 2026 sale lines, roughly $2.2 million.What was the business backdrop?United Therapeutics had just reported record full-year 2025 revenue of $3.18 billion.What was UTHR trading at later?UTHR was at $580.51 on April 17, 2026.Related CoverageHow to Read Form 4 Insider FilingsLatest Insider NewsResearch Library

## FAQ

### How much did Martine Rothblatt sell?

The visible March 2026 Form 4 sale lines totaled roughly $2.2 million.

### Was United Therapeutics still performing strongly?

Yes. The company had just reported record full-year 2025 revenue of $3.18 billion.

### Why should investors avoid overreacting?

Because the pattern looked like exercise-related monetization against a still-strong operating backdrop, not a clean abandonment of the business story.

---

Source: 13F Insight — https://13finsight.com/news/united-therapeutics-martine-rothblatt-sold-2-2m-after-record-revenue-2026-03
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-04-17T10:26:28.169Z